NEW YORK, Dec 6 – Peter Kim, a professor at MIT and a renowned proteomics experts, has decided to leave academia to head Merck’s research operations.
An assistant to Kim confirmed the move. Neither he nor a Merck spokesperson was immediately available for comment.
The move, first reported in The Wall Street Journal on Wednesday, is seen as signaling the pharmaceutical giant’s increased efforts to strengthen its proteomics initiative.
Kim is the principle investigator for a group at the Whitehead Institute that studies protein-protein interactions as well as biological process within proteins. He is also a member of the NIH’s AIDS Vaccines Research Committee.
Kim will eventually replace Edward Scolnick, Merck’s current research chief. In the meanwhile he will report to Scolnick and head the company’s internal drug discovery and development.